Features of the pathogenesis and treatment of diabetes mellitus during the COVID-19 pandemic


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The association of diabetes mellitus (DM) with an increased risk of various infectious diseases has been firmly established. DM (both type 1 and type 2) is considered to be one of the risk factors for severe COVID-19 and death from this infection. DM and COVID-19 mutually aggravate each other. The mechanisms of development of hyperglycemia and DM associated with COVID-19 infection are diverse. They include the direct damaging effects of the SARS-CoV-2 virus on pancreatic в-cells, stress hyperglycemia, glucocorticoid-induced diabetes, as well as the unmasking of previously undiagnosed DM. This article presents some aspects of the broad problem of the relationship between DM and COVID-19 infection. The article provides information on the possibilities of using different classes of hypoglycemic drugs (metformin, sulfonylurea drugs, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, insulin drugs) during COVID-19 infection, which makes this study rather relevant for practical healthcare. In the article, the authors also present their own data on the analysis of the frequency of hyperglycemia and DM in persons with COVID-19 infection of varying severity, identified factors for an unfavorable prognosis of the course of DM in COVID-19 infection.

Full Text

Restricted Access

About the authors

A. E Bagriy

M. Gorky Donetsk National Medical University

Department of Internal Medicine № 2 Donetsk, DPR

E. S Mikhailichenko

M. Gorky Donetsk National Medical University

Department of Internal Medicine № 2 Donetsk, DPR

A. V Prikolota

M. Gorky Donetsk National Medical University

Department of Therapy, Faculty of Internship and Postgraduate Education n.a. prof. A.I. Dyadyk Donetsk, DPR

Kristina E. Mogilevskaya

M. Gorky Donetsk National Medical University

Email: dzkristi@yandex.com
Teaching Assistant at the Department of Therapy, Faculty of Internship and Postgraduate Education n.a. prof. A.I. Dyadyk Donetsk, DPR

References

  1. Lu R., Zhao X., Li J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74. Doi: 10.1016/ S0140-6736(20)30251-8.
  2. Игнатенко Г.А., Багрий А.Э., Оприщенко А.А. и др. Лекции по внутренним болезням в период пандемии COVID-19: учебное пособие. Донецк, 2021. 468 с.
  3. Steenblock Ch., Schwarz P.E.H., Ludwig B., et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021;9(11):786-98. Doi: 10.1016/ S2213-8587(21)00244-8.
  4. Das S., Anu K.R., Birangal S.R., et al. Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. Life Sci. 2020;258:118202. Doi: 10.1016/j. lfs.2020.118202
  5. Guo Y.R., Cao Q.D., Hong Z.S., et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7:1-10. doi: 10.1186/s40779-020-00240-0.
  6. Davis H.E., Assaf G.S., McCorkell L., et al. Characterizing long COVID in an international: 7 months of symptoms and their impact. EClini-calMedicine. 2021;38:101019. Doi: 10.1016/j. eclinm.2021.101019.
  7. Nalbandian A., Sehgal K., Gupta A., et al. Postacute COVID-19 syndrome. Nature Medicine. 2021;27(4):601-15. doi: 10.1038/s41591-021-01283-z.
  8. Smati S., Tramunt B., Wargny M., et al. COV1D-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study. Curr Diab Rep. 2022;22(2):53-63. Doi: 10.1007/ s11892-022-01452-5.
  9. Zhou F, Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3.
  10. Yang J.K., Feng Y., Yuan M.Y, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623-28. doi: 10.1111/j.1464-5491.2006.01861.x.
  11. Alqahtani F.Y., Aleanizy F.S., Ali El Hadi Mohamed R., et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: A retrospective study. Epidemiol Infect. 2018;147:e35. Doi: 10.1017/ S0950268818002923.
  12. Singh A.K., Gillies C.L., Singh R., et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(10):1915-24. Doi: 10.1111/ dom.14124.
  13. Vas P.R.J., Hopkins D., Feher M.D., et al. Diabetes, obesity and COVID-19: a complex interplay. Diabetes Obes Metab. 2020;22(10):1892-96. doi: 10.1111/dom.14134.
  14. Williamson E.J., Walker A.J., Bhaskaran K., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-36. Doi: 10.1038/ s41586-020-2521-4.
  15. Semenzato L., Botton J., Drouin J., et al. Chronic diseases, health conditions and risk of COVID- 19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet. 2021;8:100158. Doi: 10.1016/j. lanepe.2021.100158.
  16. Fadini G.P, Morieri M.L., Longato E., et al. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Investig. 2020;43(6):867-869. doi: 10.1007/s40618- 020-01236-2.
  17. Apicella M., Campopiano M.C., Mantuano M., et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782-92. doi: 10.1016/S2213-8587(20)30238-2.
  18. Игнатенко Г.А., Багрий А.Э., Оприщенко А.А. и др. Сахарный диабет: руководство для врачей. Донецк, 2022. 640 с. [Ignatenko G.A., BagrijA.E., Oprishhenko A.A. et al. Diabetes mellitus: a guide for physicians. Donetsk, 2022. 640 р. (In Russ.)]
  19. Mallapaty S. Mounting clues suggest the coronavirus might trigger diabetes. Nature. 2020;583:16-7. doi: 10.1038/d41586-020-01891-8.
  20. Smati S., Tramunt B., Wargny M., et al. COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study. Curr Diab Rep. 2022;22(2):53-63. Doi: 10.1007/ s11892-022-01452-5.
  21. Cariou B, Hadjadj S., Wargny M., et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500-15. doi: 10.1007/s00125-020-05180-x.
  22. Cariou B., Pichelin M., Goronflot T., et al. Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study. Diabetes Res Clin Pract. 2021;175:108695. doi: 10.1016/j.diabres.2021.108695.
  23. Pornet C, Bourdel-Marchasson I., Lecomte P., et al. Trends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (The 2001 and 2007 ENTRED Surveys). Diabetes Metab. 2011;37(2):152-61. doi: 10.1016/j.diabet.2011.02.001.
  24. Wargny M, Gourdy P, Ludwig L., et al. Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study. Diabetes Care. 2020;43(11):e174-77. doi: 10.2337/dc20-1217.
  25. Vangoitsenhoven R., Martens P.J., van Nes F., et al. No evidence of increased hospitalization rate for covid-19 in community-dwelling patients with type 1 diabetes. Diabetes Care. 2020;43(10):e118-19. doi: 10.2337/dc20-1246.
  26. Ruan Y, Ryder R.E.J., De P, et al. A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. Diabetologia. 2021;64(8):1717-24. doi: 10.1007/s00125- 021-05463-x.
  27. Lim S, Bae JH, Kwon HS et al. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11-30. doi: 10.1038/s41574- 020-00435-4.
  28. Cheng X., Xin S., Chen Ya., et al. Effects of metformin, insulin on COVID-19 patients with preexisted type 2 diabetes: A multicentral retrospective study. Life Sciences. 2021;275:119371. doi: 10.1016/j.lfs.2021.119371.
  29. Guardado-Mendoza R., Salazar-Lopez S.S., Alvarez-Canales M., et al. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial. Metabolism. 2020;104:154054. doi: 10.1016/j.metabol.2019.154054.
  30. Дедов И.И., Мокрышева Н.Г, Шестакова М.В., и др. Контроль гликемии и выбор антигипергликемической терапии у пациентов с сахарным диабетом 2 типа и COVID-19: консенсусное решение совета экспертов Российской ассоциации эндокринологов. Сахарный диабет. 2022;25(1):27-49.
  31. Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and otherlineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562-69. doi: 10.1038/s41564-020-0688-y.
  32. Solerte S.B., D'Addio F., Trevisan R., et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter case-control retrospective observational study. Diabetes Care. 2020;43(12):2999-3006. Doi: 10.2337/ dc20-1521.
  33. Mirani M., Favacchio G, Carrone F, et al. Impact of comorbidities, glycemia at admission, and DPP-4 inhibitors in type 2 diabetic patients with COVID-19: a case series from an academic hospital in Lombardy, Italy. Diabetes Care. 2020;43(12):3042-49. doi: 10.2337/dc20-1340
  34. Dalan R., Ang L.W., Tan W.Y.T., et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur. Heart J. Cardiovasc. Pharmacother. 2021;7(3):e48-e51 doi: 10.1093/ehjcvp/pvaa098.
  35. Kosiborod M.N., Esterline R., Furtado R.H.M., et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586-94. doi: 10.1016/S2213-8587(21)00180-7.
  36. Bornstein S.R., Rubino F., Khunti K., et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-50. doi: 10.1016/S2213-8587(20)30152-2.
  37. Жмеренецкий К.В., Витько А.В., Петричко ТА. и др. Сложные вопросы ведения пациентов с COVID-19, коморбидных по сердечно-сосудистым заболеваниям и сахарному диабету 2-го типа. Дальневосточный медицинский журнал. 2020;2:102-114.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies